The Federal Antimonopoly Service has agreed on the price of the drug Likrinta (INN linagliptin) for the treatment of diabetes. The agreed price has been reduced by 9% compared to the registered price of the foreign reference drug Tragenta, which is included in the Vital and Essential Drugs list.
The price for a package of a domestic generic of 30 tablets in a dosage of 5 mg was agreed upon at 1,360 rubles. At the same time, the cost of a similar dosage of the reference drug Tragenta is registered at 1,501 rubles. The original drug is owned by the German company Boehringer Ingelheim and was first registered in the Russian Federation in 2012, and re-registered in 2023.
